Atlas Trials

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Clinical trial NCT01754870 · WITHDRAWN

Trial details

NCT number
NCT01754870
Sponsor
University of Wisconsin, Madison
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Start date
2013-11-01
Primary completion
2014-08-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.